Abdulraheem Yacoub, MD, University of Kansas Medical Center, Kansas City, KS, discusses JAK inhibitor-related anemia in patients with myelofibrosis, explaining that while short-term anemia may be acceptable, inducing transfusion dependence is detrimental to quality of life and prognosis. Dr Yacoub hopes this issue can be addressed through more effective JAK inhibitors, smart combinations with anemia therapies, and emerging agents such as selective JAK inhibitors, type II JAK inhibitors, and calreticulin-directed therapy. This interview took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, D.C.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.